Rivaroxaban treatment among children with cancer-associated thromboembolism: Real-world data.

Autor: Barg AA; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; National Hemophilia Center, Thrombosis Unit and Amalia Biron Research Institute of Thrombosis and Hemostasis, Sheba Medical Center, Tel Hashomer, Israel.; Department of Pediatric Hematology, Oncology & BMT, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel., Levy-Mendelovich S; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; National Hemophilia Center, Thrombosis Unit and Amalia Biron Research Institute of Thrombosis and Hemostasis, Sheba Medical Center, Tel Hashomer, Israel.; Sheba Talpiot Medical Leadership Program., Gilad O; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Department of Pediatric Hematology-Oncology, Schneider Children's Medical Center of Israel, Petach Tikva, Israel., Yacobovich J; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Department of Pediatric Hematology-Oncology, Schneider Children's Medical Center of Israel, Petach Tikva, Israel., Tamarin I; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; National Hemophilia Center, Thrombosis Unit and Amalia Biron Research Institute of Thrombosis and Hemostasis, Sheba Medical Center, Tel Hashomer, Israel.; The Dworman Automated-Mega Laboratory, Sheba Medical Center, Tel-Hashomer, Israel., Budnik I; Department of Pathophysiology, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia., Golan H; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Department of Pediatric Hematology, Oncology & BMT, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel., Toren A; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Department of Pediatric Hematology, Oncology & BMT, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel., Kenet G; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; National Hemophilia Center, Thrombosis Unit and Amalia Biron Research Institute of Thrombosis and Hemostasis, Sheba Medical Center, Tel Hashomer, Israel.
Jazyk: angličtina
Zdroj: Pediatric blood & cancer [Pediatr Blood Cancer] 2022 Oct; Vol. 69 (10), pp. e29888. Date of Electronic Publication: 2022 Jul 20.
DOI: 10.1002/pbc.29888
Abstrakt: This is the first study examining real-life data of pediatric cancer patients treated with rivaroxaban. Children with thrombocytopenia and high bleeding risk were excluded from previous clinical trials. Data regarding the safety and efficacy of rivaroxaban in pediatric cancer-associated thrombosis are scarce. Our case series included 16 children aged 7.5-17 years. Thrombus resolution rate in our study was comparable to results of previous studies. However, higher rates of thrombotic and bleeding complications were seen in our study as compared to previous reports, especially among patients with relapsed or refractory disease.
(© 2022 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: